Transit brings predictable locked rate stablecoin conversion to platforms managing stablecoin balances
across major stablecoins, including USDC, USDG, and PYUSD

NEW YORK, July 14, 2026 — Paxos Labs, the enterprise-grade stablecoin infrastructure provider, today announced the launch of Amplify Transit (“Transit”), stablecoin conversion technology that enables platforms, protocols, and treasuries to move between major stablecoins across chains at predictable fees and locked rates. By providing the infrastructure for stablecoin conversion and movement, Transit allows platforms to maintain control over their customer relationships, interfaces, and margins. Already live and operating at scale, Transit has moved almost $30 million (as of July 13) on Robinhood Chain since going live on July 1, 2026.

Through a single API integration, Transit enables platforms to convert between USDC, USDG, and PYUSD with guaranteed output amounts and around-the-clock availability. Transit is chain-agnostic by design and initially supports movement across Ethereum and Robinhood Chain. Additionally, Amplify Transit has been selected as the integration of choice for Morpho, Jumper, Across, and Arcus as they build on Robinhood Chain.

“Stablecoin adoption has reached a point where issuance is only the beginning,” said Bhau Kotecha, Co-Founder at Paxos Labs. “As platforms manage more stablecoins across more chains, they need infrastructure that allows them to move those assets predictably and efficiently. We built Transit to give platforms predictable economics at any scale while allowing them to maintain control over the experience and value they provide to their customers.”

As platforms begin supporting multiple stablecoins and operating across multiple chains, moving between those assets becomes increasingly complex and fragmented. A payments company may settle in PYUSD, a trading desk may hold USDC, and an exchange may operate on USDG, yet all of these assets must be converted, moved and unified before platforms can effectively put them to use.

Transit gives platforms a predictable way to manage this movement at scale. Exchanges, wallets, treasuries, fintechs, and protocols managing stablecoin balances receive a fixed fee per route, regardless of the size of the transaction, while rates are locked at the time of submission to guarantee the output amount before settlement. Conversions are available around the clock, including nights, weekends, and holidays, matching the always-on nature of the markets it serves.

“Robinhood Chain shows that stablecoins are becoming central to new financial ecosystems, and the volume Transit has already powered demonstrates the need for infrastructure that can move assets predictably from day one. Transit gives platforms the flexibility to support that growth while maintaining control over their economics and customer experience,” added Kotecha.

Transit adds to Paxos Labs’ product suite, acting as the movement layer of Amplify, the company’s infrastructure stack for platforms that want to mint, move and monetize digital assets. Amplify platforms can launch branded stablecoins, move between stablecoins and chains through Transit, and put stablecoin balances to work through Amplify Earn, all through a single integration.

ABOUT PAXOS LABS
Paxos Labs is the enterprise-grade stablecoin monetization infrastructure provider that gives platforms the tools to mint, move, and monetize digital assets, making them productive for their users. Its flagship product, the Amplify Suite, is a single integration to mint branded stablecoins, orchestrate stablecoin movement across chains, and embed yield. Incubated within Paxos and built on its $180B+ track record in tokenization and more than a decade of regulatory expertise, Paxos Labs brings institutional trust and rigor to the integration layer that makes stablecoins composable and accessible for the platforms building on them.

For more information visit paxoslabs.com

Media Contact
[email protected]

SOURCE Paxos Labs

NEW YORK, July 14, 2026 — Job Research Foundation, which seeks to help find a cure and treatments for Job Syndrome, has announced the ninth round of grant funding. The Foundation will award up to two grants in the amount of $200,000 each over a two-year period for scientific research into the causes of, and treatments for, Job Syndrome. To date, the organization has funded a total of seventeen research projects across the world.

Grant applications can be found online at https://www.jobresearchfoundation.org/grant-proposal-application. The deadline to apply is October 16, 2026.

The long-term goal of the Foundation is to help advance research to find a cure for Job Syndrome, a rare multisystem immunodeficiency disorder. In the short term, the Foundation hopes the research will improve the treatments for current patients. Previous applicants are encouraged to re-apply as well as collaborate with other institutions to expand their research. The application process is open to researchers worldwide and awardees will be announced in January 2027.

Also known as Autosomal Dominant Hyperimmunoglobulin E Syndrome (AD-HIES), Job Syndrome was discovered in 1966 and is a rare multisystem immunodeficiency disorder found in males and females worldwide. Visit https://www.jobresearchfoundation.org/ for additional details.

MEDIA CONTACT: Risa B. Hoag, GMGPR, 845-627-3000, [email protected]

SOURCE Job Research Foundation

IRVINE, Calif., July 14, 2026 — TiaLinx, Inc., a leader in advanced sensing, autonomous surveillance, and space‑domain intelligence technologies, today announced that Maj. Gen. Clinton E. Crosier, USAF/USSF (Ret.), has joined the company’s Advisory Board. Maj. Gen. Crosier brings more than three decades of senior leadership experience across national security space operations, Space Domain Awareness (SDA), strategic force development, and advanced cloud technology applications.  

Maj. Gen. Crosier’s distinguished career includes serving as the Director of Space Force Planning and the principal architect of the creation of the United States Space Force. He previously served as Deputy Director of Operations at U.S. Strategic Command, where he oversaw the operational acceptance and early employment of the Geosynchronous Space Situational Awareness Program (GSSAP). As Director of Requirements for the U.S. Air Force (HAF/A5R), he led the development and approval of the original requirements for the SILENT BARKER program—two of the most consequential SDA capabilities fielded in the last decade.

 “We are honored to welcome Maj. Gen. Crosier to the TiaLinx Advisory Board,” said Dr. Fred Mohamadi, Founder and CEO of TiaLinx. “His operational insight, strategic vision, and deep understanding of SDA architectures will be invaluable as we advance our next‑generation sensing and autonomous intelligence platforms. His experience transitioning space‑based surveillance systems from concept to operational reality aligns directly with TiaLinx’s mission.”

Maj. Gen. Crosier is also the Founder and CEO of DeltaV Strategies and was the inaugural leader of the $1B Aerospace & Satellite business at Amazon Web Services, where he helped accelerate cloud adoption across the global space and geospatial industries for thousands of customers on six Continents.   

“I am excited to join TiaLinx at this pivotal moment,” said Maj. Gen. Crosier. “The company’s innovative approach to wide‑field sensing, autonomous processing, and scalable space‑domain intelligence has the potential to meaningfully enhance national security space operations. I look forward to supporting the team as they continue to push the boundaries of what is possible.”

Maj. Gen. Crosier’s appointment strengthens TiaLinx’s strategic advisory capabilities as the company expands its portfolio of advanced radar, electro‑optical, and AI‑driven surveillance technologies for government and commercial customers.

 TiaLinx develops advanced AI-assisted sensing, autonomous surveillance, and space‑domain intelligence systems that enable persistent awareness across air, ground, and orbital environments. With a strong intellectual‑property foundation and a history of innovation, TiaLinx delivers mission‑critical technologies for national security and commercial applications.

Media Contact:
Fred Mohamadi
949-285-6255
[email protected]

SOURCE TiaLinx, Inc.

Strategic investment will speed the rollout of Hexivon’s technology designed to eliminate PFAS in water for good

DALLAS, July 14, 2026 — Strategic investment will speed the rollout of Hexivon’s technology designed to eliminate PFAS in water for good

Hexivon, a Dallas-based water technology company, today announced a new investment from Hillwood, a Perot company. Hexivon eliminates polyfluoroalkyl substances (PFAS), also known as “forever chemicals,” from water rather than just filtering them out. The investment expands Hillwood’s infrastructure portfolio into advanced water technologies as utilities, industry and government agencies seek long-term solutions to the PFAS problem.

“We invested in Hexivon because we believe the company has developed a disruptive approach to addressing one of the most pressing environmental challenges facing communities today. We believe this collaboration can help accelerate adoption of meaningful PFAS treatment solutions across the country.”

— Ross Perot, Jr., Chairman of Hillwood

The only proven system that pulls PFAS from flowing water and destroys it for good

Most methods move PFAS around. Carbon filters, ion exchange, and reverse osmosis pull PFAS out of water, but leave waste that must be hauled off and stored. Hexivon works differently. It works at any ambient temperature and destroys PFAS at the molecular level on site. It breaks the chemicals apart and leaves nothing harmful behind.

In a 2025 pilot in Cary, North Carolina, drinking water tested at 40 parts per trillion of PFAS. After Hexivon treatment, the level was non-detectable. The system cleaned 150,000 gallons per day and made zero waste. Independent, EPA-certified labs checked the results.

Collaboration built to bring the technology to market and meet growing demand

“Hillwood brings far more than capital to this relationship. Their experience developing complex infrastructure projects, working with public-sector stakeholders and deploying long-term investment capital makes them an ideal strategic partner as we accelerate commercialisation of our PFAS destruction technology.”

— Kevin Boscamp, Chairman of Hexivon

Demand for PFAS treatment is growing fast. It is driven by new federal regulations and increased investment in water projects. In Texas, House Bill 500 (HB500) sent more than $1 billion to the Texas Water Development Board for water projects, including PFAS cleanup. Across Dallas-Fort Worth, 29 public water systems have exceeded EPA standards for PFAS, underscoring the need for treatment solutions and funding.

Together, Hillwood and Hexivon plan to accelerate deployment of PFAS destruction systems. The goal is simple: cleaner water for municipal, industrial and government customers across the United States.

Funding is available for Dallas-Fort Worth Water Systems

Texas HB500 funding can help pay for PFAS treatment in your community, and Hexivon is ready to help your system apply. The deadline is July 30, so time is short. Hexivon connects qualifying DFW water systems with engineering partners to guide the HB500 application, at no charge.

Contact Hexivon to connect with an engineering partner:
[email protected]
949-503-9341

About Hexivon
Hexivon is a Dallas-based water technology company focused on the treatment and destruction of PFAS and other emerging contaminants. Through its proprietary treatment platform, the company serves municipal utilities, industrial facilities, government agencies and environmental remediation projects across the United States. Learn more at hexivon.com.

About Hillwood
Hillwood, a Perot company, is one of the nation’s leading real estate development and investment firms with expertise spanning industrial, commercial, residential and public-sector infrastructure projects. Since 1988, Hillwood has developed and invested in transformative projects throughout North America, creating long-term value through strategic development, infrastructure investment and capital deployment.

Media Contact:
Braden Reddall
510-604-7535

SOURCE Hexivon

Hospital investors lead oversubscribed financing

DURHAM, N.C., July 14, 2026 — 410 Medical, Inc., a medical device company focused on innovative technologies for emergency and critical care, today announced the completion of a $12 million financing round. Orlando Health Ventures led the round, with participation from Hatteras Venture Partners, Ballad Health, OSF Healthcare, Rex Health Ventures, CU Healthcare Innovations Fund, Sarnova, Catalyst by Wellstar, Tampa General, and a new undisclosed strategic investor.

The new funding will be used to scale 410 Medical’s commercial operations and support the launch of LifeFlow’s next-generation infuser.

“The heightened interest in this round reflects the confidence investors and customers have in 410 Medical’s mission and products,” said Kyle Chenet, Chief Executive Officer at 410 Medical. “With this funding, we’re able to expand our commercial reach, bringing LifeFlow to more clinicians and investing in the next generation of our technology. We’re grateful to Orlando Health Ventures for leading this round and excited to welcome Tampa General and an additional strategic partner to our syndicate.”

Backing Continued Commercial Growth

410 Medical’s LifeFlow products are used by more than 500 hospitals and EMS agencies across the country to help clinicians deliver fluid and blood quickly and effectively for patients experiencing sepsis, hemorrhagic shock, and other life-threatening conditions. Nearly 80,000 patients have been treated using LifeFlow. This financing enables the company to accelerate LifeFlow adoption and reach into new hospital systems and EMS agencies nationwide.

“Orlando Health Ventures is proud to lead this round and deepen our partnership with 410 Medical,” said Bobby Helmedag, Managing Director of Orlando Health Ventures. “LifeFlow addresses a critical gap in resuscitative care, and we’ve seen firsthand the impact it can have for clinicians and patients. We’re excited to support the team as they scale commercial operations and advance the next generation of the LifeFlow infuser.”

Investing in the Next Generation of LifeFlow

Alongside its commercial expansion, 410 Medical is investing in the future expansion of LifeFlow technologies. The next-generation device, planned for launch in 2027, builds on feedback from nearly ten years of experience partnering with front-line medical providers working tirelessly to provide effective resuscitation for critically ill patients. Speed, portability and ease of use are essential in these moments. The new LifeFlow technology will address these and other unmet needs. 

About 410 Medical, Inc.

Founded in 2013, 410 Medical is a North Carolina-based medical device company focused on advanced resuscitation technologies to improve the care of critically ill patients. Our lead product LifeFlow^® received FDA clearance in 2016 and is used to enhance the administration of fluid and blood products for patients with sepsis, hemorrhagic shock, and other life-threatening conditions. 410 Medical is committed to providing innovative technologies, education, and support for emergency and critical care providers to deliver effective resuscitation when minutes matter.

For more information visit www.410medical.com

Media Contact:
Carla Hoffman
[email protected]

SOURCE 410 Medical, Inc.

The Corgi SK Hynix 2x Daily ETF (Cboe BZX: SK) has the lowest expense ratio of any 2x long SK Hynix ETF, at 0.50%, compared with 0.75% to 1.50% for other 2x long SK Hynix ETFs now trading.*

NEW YORK, July 14, 2026 — Corgi, an AI fintech startup, announced that the Corgi SK Hynix 2x Daily ETF (Cboe BZX: SK) is now trading on Cboe BZX Exchange. The Fund seeks daily investment results, before fees and expenses, corresponding to 2x the daily performance of the American Depositary Receipt (ADR) of SK hynix Inc. (Nasdaq: SKHY).

At a 0.50% net expense ratio, the Corgi SK Hynix 2x Daily ETF is the lowest-cost of the U.S.-listed 2x long ETFs on the ADR of SK hynix Inc. now trading.*

The Lowest-Cost Way to Trade 2x SK Hynix

For investors searching for the lowest-cost 2x SK Hynix ETF, the Corgi SK Hynix 2x Daily ETF (SK) offers the lowest expense ratio in the category at 0.50%.* Competing 2x long SK Hynix ETFs carry net expense ratios of 0.75% (Leverage Shares SKHX), 0.95% (ProShares SKHU), 1.25% (T-REX HYNX), and 1.50% (GraniteShares SKUU), as of July 14, 2026 and subject to change.* In daily leveraged products, where positions are actively rebalanced and trading costs can affect fund expenses over time, the expense ratio is an important consideration for investors.

Why SK Hynix

SK hynix Inc. is currently one of the world’s largest memory semiconductor suppliers and a leading producer of the high-bandwidth memory (HBM) that AI accelerators depend on. The Corgi SK Hynix 2x Daily ETF seeks to give investors 2x daily exposure to this single name in a listed, transparent, exchange-traded structure, and is intended for sophisticated investors who monitor their positions daily.

“Costs are an important consideration for investors using daily leveraged ETFs, and our goal is to give investors access to leverage at a competitive cost,” said Anthony Crinieri, Portfolio Manager at Corgi Funds. “SK joins a broad lineup of more than 175 leveraged ETFs, as of July 14, 2026, designed to give investors access to leveraged investment strategies at competitive expense ratios.”

The Fund is listed on Cboe BZX Exchange and can be bought and sold throughout the trading day through broker-dealers and other financial intermediaries. Investors may pay brokerage commissions and may also incur platform, custodial, advisory, and other fees or expenses charged by their financial intermediary. Leveraged ETFs involve significant risk and are designed primarily for sophisticated investors managing positions daily. Expense ratios are only one factor to consider when evaluating an investment.

About Corgi

Founded in 2025, Corgi is an AI Financial Infrastructure Company seeking to create innovative products in insurance and finance. We are seeking to build the foundation for a new generation of financial services, with AI and technology at the core from day one. To learn more about Corgi, follow us on LinkedIn, on X, or at www.corgifunds.com.

Important Information

Investors should consider the investment objectives, risks, charges and expenses carefully before investing. The prospectus contains this and other information about the Fund and should be read carefully before investing. A copy of the prospectus is available at www.corgifunds.com.

Investing involves risk, including possible loss of principal. There is no guarantee that the Fund will achieve its investment objective. The Fund does not invest directly in the securities of SK hynix Inc.

Leveraged ETFs seek to provide a multiple of the daily performance of an underlying security or index, before fees and expenses. Due to daily compounding, returns over periods longer than one day may differ significantly from the stated multiple.

The Fund seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of its underlying security for a single day. This is measured from one net asset value calculation to the next. The Fund does not seek to achieve its stated investment objective over periods longer than one trading day. Due to the effects of compounding, the Fund’s performance over periods longer than one day may differ significantly from two times (2x) the performance of the underlying security over the same period, particularly during periods of increased market volatility.

The use of leverage magnifies both gains and losses and may result in significant losses. A relatively small movement in the underlying security can result in a substantially larger movement in the value of the Fund’s shares. The underlying ADR may experience heightened volatility, particularly in the initial period following its U.S. listing. The Fund uses derivatives, including swap agreements, to obtain leveraged exposure, which may expose the Fund to additional risks, including counterparty risk, liquidity risk, valuation risk, and tracking error. The Fund is non-diversified and concentrates its exposure in a single issuer, so the Fund’s performance depends heavily on the performance of that one security and will be more volatile than a diversified fund. The Fund is intended for sophisticated investors who understand the risks associated with leveraged investment strategies and who intend to monitor and manage their investments actively. The Fund is not intended for buy-and-hold investors.

Depositary Receipts Risk. The Fund obtains exposure through instruments referencing sponsored depositary receipts. A depositary receipt’s market value may diverge from the underlying common stock because the two trade in different markets, hours, and currencies. Depositary receipts carry the credit, custody, and operational risk of the depositary bank, and currency fluctuations between the U.S. dollar and the South Korean won will affect their value.

SK hynix Inc. is not affiliated with Corgi Strategies, LLC, Corgi, or Paralel Distributors, LLC, and has not sponsored, endorsed, sold, or promoted the Fund and makes no representation regarding the advisability of investing in the Fund.

The Fund is newly organized and has limited or no operating history. ETF shares trade at market price (not NAV), are not individually redeemable, and may trade at a premium or discount to NAV. Brokerage commissions will reduce returns.

This release is informational only and not an offer or solicitation; offers are made only by prospectus.

*Expense ratio comparison among U.S.-listed 2x long ETFs on the ADR of SK hynix Inc., based on net expense ratios obtained from each fund’s prospectus, fact sheet, and fund page as of July 14, 2026: Corgi SK Hynix 2x Daily ETF (SK) 0.50%; Leverage Shares 2x Long SK Hynix Daily ETF (SKHX) 0.75%; ProShares Ultra SK Hynix ETF (SKHU) 0.95%; GraniteShares 2x Long SK Hynix Daily ETF (SKUU) 1.50%; T-REX 2X Long SK Hynix Daily Target ETF (HYNX) 1.25%. Expense ratios are subject to change and new funds may launch, which could affect these comparisons.

Paralel Distributors, LLC (Member FINRA/SIPC) is the distributor. Corgi Strategies, LLC is the adviser. Paralel is unaffiliated with Corgi Strategies, LLC and Corgi. Control No.: COR122

Media Contact

Erika Lee
Corgi Funds
[email protected]

Justin Graiber
Corgi Funds
[email protected]

SOURCE Corgi Funds

Investment will Fuel Expansion and Accelerate Development of the Company’s Comprehensive Security Platform

PHILADELPHIA, July 14, 2026 — ZeroEyes, creators of the leading multi-analytics weapons detection and threat intelligence platform, today announced a planned $10 million U.S. investment in AI/ML research and development. This includes a commitment to hiring over 100 veterans in Southeastern Pennsylvania over the next 24 months to fill the roles of Technical Program Managers (AI), MLOps Engineers, and AI Solutions Specialists. The company made the announcement at Senator Dave McCormick’s 2026 Pennsylvania Defense and Innovation Summit, being held today and tomorrow at Army War College in Carlisle, Pennsylvania.

The investment will fund additional expansion, including:

• The company’s state-of-the-art, 3,000 sq. ft. experimental AI technology lab that gives ZeroEyes the ability to generate unparalleled data, perform live demos, and test its AI weapons detection models and hardware in any environment
• The Conshohocken-based ZeroEyes Operations Center (ZOC), the industry’s only in-house operations hub staffed primarily by military and law enforcement veterans, including former special forces personnel
• Small drone technology capabilities, including 3D environment mapping, threat detection (ZeroEyes Aerial Detection [ZAD] Kit), and active shooter disorientation (Drones/Robots for Active Shooter Deterrence [DRASD])

Over the past few months, ZeroEyes has expanded its platform beyond firearm detection to deliver a broader, more intelligent approach to safety. New analytics capabilities including knife detection and real-time threat geolocation, as well as additional security offerings, mark a significant step toward unifying acute threat detection with everyday safety operations. The new capabilities reflect ZeroEyes’ goal to become a single, trusted platform organizations will use to secure, detect, and respond to a wide range of critical security events. These continued investments showcase the company’s commitment to further developing a comprehensive security platform that integrates preparedness, operational awareness, and investigative insights.

“This investment marks a critical milestone in our evolution into a unified threat intelligence platform that provides organizations with a single, trusted ecosystem for threat response,” said Mike Lahiff, CEO and co-founder of ZeroEyes. “We are excited to accelerate our technology roadmap while deepening our commitment to the veteran community within our home of Southeastern Pennsylvania.”

About ZeroEyes
ZeroEyes delivers an integrated suite of analytics and security tools, including capabilities such as weapons detection, real-time threat geolocation and more, designed to enhance preparedness, accelerate threat identification, and enable effective response. It provides real-time detection and actionable information for visibly brandished weapons, such as guns and knives, and alerts local staff and law enforcement with images and precise location often in a matter of seconds from the moment a gun is detected.

Founded in 2018 by Navy SEALs and elite technologists, the company pioneered human-verified gun detection to help organizations mitigate and respond to gun-related incidents. Its patented technology has been recognized by the U.S. Department of Homeland Security (DHS) as an effective anti-terrorism solution and was the first AI-based gun detection platform to achieve full SAFETY Act Designation. Building on its proven success in firearm detection, having verified over thousands of accurate firearm detections, ZeroEyes expanded its platform to address the full spectrum of modern security challenges, from defending to detecting and responding to threats.

ZeroEyes’ platform is deployed in thousands of locations across SLED, federal and defense, and commercial enterprise customers in the US, Mexico, the Caribbean, Latin America (LATAM), and India. The company also provides security assessments, system integration support, and active shooter preparedness training. Headquartered in the Greater Philadelphia area, the company continues to advance its platform using a proprietary dataset of millions of images and videos, delivering high accuracy and reliability as security needs evolve. Learn more at ZeroEyes.com.

SOURCE ZeroEyes

• First production-ready chiplet portfolio spanning connectivity, power, and memory for XPUs
• Reduces custom AI silicon development time and cost by up to 50% from architecture to high-volume manufacturing
• Tier-1 customer engagements validate technology readiness and market opportunity

SAN JOSE, Calif., July 14, 2026 — Today, TYLsemi^TM emerged from stealth and announced the closing of an oversubscribed $43 million early-stage funding round to accelerate the development of AI infrastructure. TYLsemi is the first chiplet platform company to deliver a full portfolio across IO, power delivery, and memory paired with a chiplet-based custom silicon design, integration and supply-chain ownership. This standards-based, production-ready portfolio will provide AI infrastructure customers with a faster, lower-risk path for developing AI silicon from architecture to deployment.

The funding round was led by Matter Venture Partners with participation from Viola Ventures, GHOVC, Egis Technology, and strategic investment from leading companies across the global semiconductor and AI infrastructure ecosystem. The company was co-founded by industry leaders Mohit Gupta and Sunil Bhardwaj, who have led and scaled businesses and worldwide engineering and operations teams at Alphawave (acquired by Qualcomm), SiFive, Cadence Design Systems, Rambus, and other leading semiconductor companies.

“The AI accelerator market is on track to reach $604 billion by 2033 and custom silicon XPUs built for specific hyperscaler workloads are the fastest-growing segment,” said Mohit Gupta, Founder and CEO of TYLsemi. “At that scale, chiplet-based design is no longer optional, yet there is no pure-play chiplet company serving this market with a full portfolio. TYLsemi closes that gap with standards-based chiplets combined with UCIe-based die-to-die connectivity, XPU-aware design, packaging, and integration — giving customers a fast, proven path to AI-era silicon.”

Chiplets are the New Standard for AI Silicon

AI systems are shifting from monolithic chips to distributed, multi-die architectures as chip size approaches physical limits and connectivity and power become bottlenecks. At the same time, advances in packaging technologies are making it possible to integrate multiple dies into a single system. With the emergence of standardized interconnects such as UCIe, chiplet-based design is now practical and scalable. 

“AI infrastructure is undergoing a fundamental shift toward modular, chiplet-based design, but the ecosystem has not kept pace,” said Jim Handy, General Director at Objective Analysis. “This represents a significant opportunity for a company such as TYLsemi that can deliver pre-validated, standards-based silicon to accelerate AI infrastructure silicon deployment.”

TYLsemi Makes Chiplet-Based AI Systems Practical at Scale

TYLsemi delivers a reusable production-ready chiplet portfolio that simplifies the design of multi-die AI systems. Customers can use these chiplets as standalone components or as the foundation for full custom silicon solutions based on leading industry foundry and packaging technologies. Below are the first chiplets that TYLsemi will bring to market, with more planned in the future to meet the evolving needs of AI infrastructure customers.

• TYL.IO^TM: Versatile connectivity chiplet product family for AI systems
  Comprehensive family of IO chiplets designed to enable high-bandwidth, standards-based connectivity across high-performance systems supporting PCIe, ESUN, and UALink connectivity today, with a co-packaged optics (CPO) roadmap for next-generation rack-scale fabrics.
• TYL.Power^TM: Intelligent in-package power delivery solution for XPUs
  An integrated voltage regulator (IVR) chiplet that provides efficient and intelligent control and optimized system-level power efficiency
• TYL.Mem^TM: Versatile memory connectivity product family for AI systems
  A planned product family focused on memory connectivity for advanced AI systems, with additional details to be announced as the roadmap progresses.
• TYL.Forge^SM: End-to-end chiplet-enabled custom silicon platform
  A full-stack platform for customer-defined XPU, compute, and fabric designs, which TYLsemi implements using its connectivity and power delivery portfolio, plus IP, foundry, packaging, and production readiness.

TYL.IO and TYL.Power chiplet samples will be available to qualified customers in 2027 in partnership with TSMC; TYLsemi is now engaging lead customers for its TYL.Forge platform.

Supporting Quotes

“AI infrastructure is entering an era of rapid scaling, so the ability to develop advanced silicon quickly and efficiently will be a defining advantage,” said Wen Hsieh, Founding Managing Partner at Matter Venture Partners. “TYLsemi is building foundational chiplet technologies for custom silicon that will make the design process faster, less risky, and more accessible, unlocking significant value and velocity across the AI ecosystem.”

“TYLsemi has built the chiplet platform the entire AI silicon industry needs — one that can serve the scale of a hyperscaler and the speed requirements of an emerging AI company in the same breath,” said Zvika Orron, Managing Partner at Viola Ventures. “For the first time, advanced custom silicon development isn’t a competitive moat reserved for the largest players; it’s a platform.”

“TYLsemi’s standards-based chiplets democratize chip development for startups and large silicon and system developers at a much lower cost,” said Shri Dodani, Founder and Managing Partner at GHOVC. “This enables them to develop multiple chip generations in parallel to deliver custom silicon at a much faster pace.”

“As Egis advances Mobius100, our datacenter-grade compute CPU based on a leading compute architecture and 3nm class process technologies, we see chiplet-based IO, memory, and intelligent power delivery as essential building blocks for next-generation AI infrastructure,” said Steve Lo, Chairman at Egis Technology. “TYLsemi’s standards-based chiplet platform, including IO and IVR chiplets, is highly complementary to our roadmap, and we look forward to exploring opportunities to integrate these technologies into future modular, power-efficient AI infrastructure platforms.”

About TYLsemi

TYLsemi is redefining how AI infrastructure silicon is built by delivering standards-based, production-ready chiplets purpose-built for modern multi-die systems. By combining chiplet design, packaging, integration and production expertise, TYLsemi provides a scalable, low-risk path to deploying advanced AI infrastructure. Customers can use TYLsemi chiplets as standalone components or as the foundation for full custom silicon. TYLsemi is expanding teams across silicon design, packaging, and systems engineering.

For more information, visit tylsemi.ai. To explore current opportunities across silicon design, packaging, and systems engineering, visit tylsemi.ai/careers.

SOURCE TYLsemi

– Investment secures runway to reach cash flow positivity – 

NEEDHAM, Mass., July 14, 2026 — Mighty Therapeutics Holdings Inc. (the “Company” or “Mighty”), a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. The Company has entered into an agreement with K2 HealthVentures (K2HV), an alternative investment firm that provides flexible, long-term financing solutions in life sciences and healthcare, to provide a credit facility of up to $125 million, including an initial $30 million tranche. The Company has also held an initial closing of its Series B financing, in which founding investor Morningside has invested $25 million.

Mighty’s current cash and cash equivalents, together with revenues from sales of its lead commercial product, are expected to support further acceleration of its launch activities and ongoing late-stage development initiatives in dry age-related macular degeneration and polymerase gamma-related mitochondrial disease, expedite pipeline initiatives in Parkinson’s disease and long-chain fatty acid disorders, and extend cash runway into 2028. Subsequent drawdowns available under the K2HV facility are expected to secure runway to projected cash flow positivity in early 2029. 

“We are deeply gratified by Morningside’s ongoing support, and very excited to partner with K2 HealthVentures to accelerate and broaden our efforts to address the unmet medical needs of the many individuals living with diseases of mitochondrial dysfunction,” said Reenie McCarthy, Chief Executive Officer of Mighty Therapeutics. “These financings secure our access to the additional capital necessary to reach cash flow positivity, supporting our continued leadership of the burgeoning field of mitochondrial medicine across a broad range of therapeutic areas. With our strong commercial momentum and promising pipeline, we are poised for long-term growth and continued patient impact.” 

Under the K2HV credit facility, the first $30 million term loan was funded upon signing of the agreement. The second $25 million term loan is expected to be available for drawdown through early 2028, subject to the Company’s achievement of specified commercial, clinical and regulatory milestones. The third $20 million term loan is expected to be available for drawdown through early 2029, subject to the Company’s achievement of specified commercial, clinical, regulatory and financing milestones. An additional $50 million tranche is available for draw at Mighty’s option, subject to K2HV’s discretion. 

About Mighty Therapeutics 

Mighty Therapeutics, together with its wholly owned operating subsidiary, Stealth BioTherapeutics Inc., is advancing novel therapies for people living with diseases involving mitochondrial dysfunction. Grounded in rigorous science and inspired by meaningful patient partnerships, the company is building a proprietary pipeline to directly address bioenergetic deficits at the source. 

In September 2025, Mighty marked a historic milestone with the U.S. Food and Drug Administration (FDA) approval of its first commercial therapy, establishing both the first FDA-approved treatment for Barth syndrome and the first FDA-approved therapy to directly target mitochondria. 

Today, Mighty’s development portfolio encompasses rare and age-related diseases. Mighty continues to develop elamipretide in Barth syndrome, polymerase gamma related mitochondrial disease and dry age-related macular degeneration. Mighty is also progressing its next-generation clinical candidate, bevemipretide, for ophthalmic and neurological pathologies, and continues to develop preclinical assets SBT-255 and SBT-589 for rare mitochondrial disorders. For more information, visit www.mightytx.com. 

Investor Contact 
Precision AQ
Austin Murtagh
[email protected] 

Patient Advocacy 
[email protected] 

Media Contact
Ascent Strategic Communications
[email protected] 

SOURCE Mighty Therapeutics